---
title: "\"Profit Warning\" Fudan-Zhangjiang estimates a full-year loss of 120 million to 180 million RMB"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274418515.md"
description: "Fudan-Zhangjiang issued a profit warning, expecting a net loss of between 120 million and 180 million RMB for the fiscal year 2025, compared to a net profit of 39.73 million RMB in the previous year. The reason is that the group is actively promoting the progress of research and development projects, with R&D investment as a proportion of operating income continuously increasing; the product Libo Duo has not been selected for the national procurement catalog, and the company has accordingly adjusted its sales strategy to lower market retail prices, resulting in a reduction of approximately 100 million RMB in profit contribution from the products"
datetime: "2026-02-01T10:39:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274418515.md)
  - [en](https://longbridge.com/en/news/274418515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274418515.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274418515.md) | [繁體中文](https://longbridge.com/zh-HK/news/274418515.md)


# "Profit Warning" Fudan-Zhangjiang estimates a full-year loss of 120 million to 180 million RMB

Fudan-Zhangjiang (01349.HK) issued a profit warning, expecting a net loss of between RMB 120 million and RMB 180 million for the fiscal year 2025, compared to a net profit of RMB 39.73 million in the previous year. The reason is that the group is actively promoting the progress of R&D projects, with R&D investment as a proportion of operating income continuously increasing; the product Libo Duo has not been selected for the national procurement catalog, and the company has adjusted its sales strategy to lower market retail prices, resulting in a reduction of approximately RMB 100 million in profit contribution from the products

### Related Stocks

- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)
- [Fudan-Zhangjiang (688505.CN)](https://longbridge.com/en/quote/688505.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md)
- [FUDANZHANGJIANG (01349.HK)](https://longbridge.com/en/quote/01349.HK.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)

## Related News & Research

- [Fosun Pharma Unit Gets China Nod for Hematological Malignancy Drug Trial](https://longbridge.com/en/news/279052280.md)
- [06:50 ETLabConnect amplía su infraestructura de laboratorio central global con una instalación en Wuxi, China](https://longbridge.com/en/news/278867623.md)
- [China Medical System Gets China Nod to Market Renal Anaemia Drug](https://longbridge.com/en/news/279046722.md)
- [SSY Gets China Nod for Production, Registration of Vitamin Injection](https://longbridge.com/en/news/279036594.md)
- [Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results](https://longbridge.com/en/news/278713493.md)